Baxalta (NYSE:BXLT) Receives Media Impact Score of 0.08

Headlines about Baxalta (NYSE:BXLT) have trended somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Baxalta earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.4428308611514 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

TRADEMARK VIOLATION NOTICE: “Baxalta (NYSE:BXLT) Receives Media Impact Score of 0.08” was published by Week Herald and is the property of of Week Herald. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://weekherald.com/2017/12/17/baxalta-bxlt-receiving-somewhat-positive-news-coverage-study-shows.html.

About Baxalta

Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta’s categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR.

Insider Buying and Selling by Quarter for Baxalta (NYSE:BXLT)

Receive News & Ratings for Baxalta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxalta and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply